论文部分内容阅读
目的探讨血浆EBV DNA定量检测在鼻咽癌的诊断及监测鼻咽癌患者复发和转移中的临床意义价值。方法收集2009年1月-2010年12月在我院初诊为鼻咽癌的患者,应用荧光定量PCR方法检测血浆EBV DNA含量,比较治疗前后及缓解组和治疗前组、治后复发或转移组血浆EBV DNA含量的差异。结果治疗前组患者血浆EBV DNA阳性率94.73%,中位拷贝数4.13×105拷贝/ml;治疗后缓解组阳性率16.53%,中位拷贝数0拷贝/ml;治疗后复发或转移组阳性率93.90%,中位拷贝数6.17×105拷贝/ml。提示治疗前组与治疗后缓解组、治疗后缓解组相与治疗后复发或转移组比较,均有显著性差异(P<0.01)。结论血浆EBV DNA定量检测可作为鼻咽癌的诊断方法之一,亦可作为监测鼻咽癌患者治疗后复或转移的标
Objective To investigate the clinical value of quantitative detection of plasma EBV DNA in the diagnosis of nasopharyngeal carcinoma and in monitoring the recurrence and metastasis of nasopharyngeal carcinoma patients. Methods From January 2009 to December 2010, patients with newly diagnosed nasopharyngeal carcinoma (NPC) in our hospital were recruited. Fluorescent quantitative PCR was used to detect the content of EBV DNA in plasma. The levels of plasma EBV DNA were compared before and after treatment, before treatment, after treatment, before treatment, before treatment, Differences in plasma EBV DNA content. Results The positive rate of plasma EBV DNA in patients before treatment was 94.73%, and the median copy number was 4.13 × 105 copies / ml. After treatment, the positive rate of EBV DNA in remission group was 16.53%, the median copy number was 0 copies / ml. The positive rate of EBV DNA in recurrence or metastasis group 93.90%, median copy number 6.17 × 105 copies / ml. There was a significant difference (P <0.01) between pretreatment group and post-treatment remission group, post-treatment remission group phase and post-treatment recurrence or metastasis group. Conclusion Quantitative detection of plasma EBV DNA can be used as one of the methods for the diagnosis of nasopharyngeal carcinoma. It can also be used as a standard for monitoring the metastasis or metastasis of nasopharyngeal carcinoma patients